<DOC>
	<DOCNO>NCT00014274</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective transitional cell cancer urothelium . PURPOSE : Randomized phase II/III trial compare different combination chemotherapy regimens treat patient transitional cell cancer urothelium .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Transitional Cell Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : - Compare antitumor activity gemcitabine carboplatin v methotrexate , carboplatin , vinblastine patient transitional cell cancer urothelium ineligible cisplatin-based chemotherapy . - Compare toxicity acute intermediate ( 1-2 year ) side effect regimens patient . - Compare complete response rate , progression-free survival , overall survival patient treat regimen . - Compare symptom quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive methotrexate* IV vinblastine IV day 1 , 15 , 22 carboplatin IV 1 hour day 1 . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine IV 30 minute day 1 8 carboplatin IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . NOTE : * Methotrexate omit patient pleural effusion ascites complete resolution patient glomerular filtration rate le 30 mL/min creatinine great 2 mg/dL Patients either arm achieve complete response ( CR ) receive 2 additional course chemotherapy beyond CR . Quality life assess baseline , every 2 course chemotherapy , within 6 week completion therapy . Patients follow within 6 week , every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 156 patient ( 78 per treatment arm ) accrue phase II portion study . A total 225 patient accrue phase II + III portion study within 5 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell cancer urothelium , include renal pelvis , ureter , urinary bladder , urethra , meet 1 follow criterion : Unresected positive lymph node Distant metastases ( M1 , stage IV ) Unresectable primary bladder cancer ( T34 ) Measurable disease Ineligible cisplatinbased chemotherapy present follow : WHO performance status 2 AND/OR Glomerular filtration rate great 30 mL/min less 60 mL/min No brain metastasis CNS lesion PATIENT CHARACTERISTICS : Age : 18 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 125,000/mm^3 Hepatic : Bilirubin great 1.25 time normal AST/ALT great 3 time normal ( 5 time normal liver metastasis present ) Renal : See Disease Characteristics Calcium normal Other : Not pregnant nursing Fertile patient must use effective contraception 6 month study participation No psychological , familial , sociological , geographical condition would preclude study participation No prior concurrent malignancy except cure basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior systemic biologic therapy Chemotherapy : See Disease Characteristics No prior systemic cytotoxic therapy ( include adjuvant neoadjuvant chemotherapy ) Endocrine therapy : Not specify Radiotherapy : At least 3 month since prior radiotherapy Prior radiotherapy study lesion allow evidence disease progression Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>